Table 1

CRC ORsa and CIs for the CYP2E1 RsaI and insert polymorphisms

CYP2E1AllColonRectum
RsaI c1/c1 384/449b1.0271/4491.0120/4491.0
c1/c2 116/1640.8 (0.6–1.1)78/1640.8 (0.6–1.1)42/1640.9 (0.6–1.3)
c2/c2 21/260.9 (0.5–1.6)19/261.2 (0.6–2.2)3/260.4 (0.1–1.3)
P = 0.20cP = 0.48P = 0.22
any c2137/1900.8 (0.6–1.1)97/1900.8 (0.6–1.1)45/1900.8 (0.6–1.3)
Insert 0 357/4681.0261/4681.0104/4681.0
1 133/1371.3 (1.0–1.8)88/1371.2 (0.9–1.7)49/1371.7 (1.1–2.6)
2 21/320.9 (0.5–1.6)12/320.7 (0.3–1.2)9/321.4 (0.6–3.1)
P = 0.34P = 0.99P = 0.55
1 or 2154/1691.3 (0.9–1.7)100/1691.1 (0.8–1.5)58/1691.6 (1.1–2.5)
  • a Adjusted by unconditional logistic regression for age, sex, ethnicity, pack-years of cigarette smoking, lifetime recreational physical activity (hours), lifetime aspirin use (months), body mass index 5 years ago, years of schooling, and intakes of nonstarch polysaccharides from vegetables and calcium from foods and supplements.

  • b No. of cases/no. of controls. The CYP2E1 insert genotype was missing for 10 cases and 2 controls for whom DNA was depleted. Twelve cases had multiple colorectal tumors involving both colon and rectum, and these cases were included in both subsite models.

  • c P for gene-dosage effect.